IL6 and COVID-19: While in a multivariate analysis the female sex and the presence of elevated levels of interleukin-6 (IL-6) were independently associated with development of post-COVID-19 conditions (PCC), patients who received early CCP treatment (≤5 days after symptom onset) compared with late CCP treatment had statistically significant lower odds of PCC.